Navigation Links
Velos, Inc. Appoints William Broucek Senior Director, Professional Services
Date:3/12/2009

FREMONT, Calif., March 12 /PRNewswire/ -- Velos, Inc., the recognized leader and trusted resource for clinical trials management information systems, has appointed William Broucek to the position of Senior Director, Professional Services. Velos developed this role to address needs coming out of its significant growth during the past two years. Broucek was hired to ensure that superior customer service is sustained while its market leadership continues to expand.

"Excellence in meeting the singular needs of each customer has to keep pace with the excellence and reputation of our clinical research software product suite," said John S. McIlwain, President and CEO of Velos. "Broucek is safeguarding that objective as he oversees and directs our front line project managers, supporting them with strong technical expertise and resources."

Broucek is a healthcare software professional with proven success, leading professional services and operations groups to complete implementation projects of all sizes on time and within budget. Previously, Broucek held senior positions in professional services and implementation management with Bay Area companies that include Agistix, iKnowMed, a Division of US Oncology, Oacis Healthcare Systems, and Fritz Companies, Inc.

"We are very pleased to have Bill Broucek as a member of our management team," continued McIlwain. "His excellent interpersonal, analytical and leadership skills have garnered a warm respect among our project managers. This, combined with Bill's solid systems knowledge, adds depth and breadth to the services we can offer to our valued customers."

About Velos

Velos, Inc. is the trusted clinical trial management resource for investigators, sponsors and academic leaders throughout the U.S. Its customers include 21 of the top 25 academic medical centers and research institutions. Among the 100 largest recipients of NIH clinical research funding, Velos customers receive over 50% of NIH extramural grants. Velos eResearch is deployed for clinical research in all parts of the healthcare enterprise and supports a broad diversity of clinical departments and functional needs. The system fundamentally improves the way data is collected, organized and shared. A pure Internet technology platform, Velos eResearch harnesses advanced powers of the Internet to enable research sites, sponsors, and patients to collaborate in a secure, integrated system platform. System users are freed of redundant data entry and related time delays associated with most clinical research today. With emphasis on workflow, Velos integrates the clinical, administrative and financial information needs of research management. Founded in 1996, Velos is privately held with headquarters in Fremont, California. For more information, visit www.velos.com.

This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.


'/>"/>
SOURCE Velos, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. RoundTable Appoints Senior Healthcare Executives
2. BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer
3. Chiltern Appoints Jane Turner as Late Phase Director for Europe
4. American Academy of Orthopaedic Surgeons Appoints Peter Mandell, MD, Chair of the Council on Advocacy
5. Endo Pharmaceuticals Appoints William Montague to Board of Directors
6. Streamline Health Appoints Jay D. Miller to Board of Directors
7. Nyer Medical Appoints Sandra Zimmerman as Chief Financial Officer
8. Cynosure Appoints William T. Kelley as Senior Vice President of International Sales
9. American TeleCare, Inc. (ATI) Appoints Michael A. Brodeur as Chief Financial Officer
10. Laser Therapy Disappoints in Stroke Trial
11. Mardil Inc. Appoints Medical Device Veteran Daniel A. Pelak to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... , ... April 21, 2017 , ... Providing broad access ... in opposition, but there is a better way to address this problem. , That ... of Pharmacy, Public Policy and Economics at the University of Southern California, who served ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... finds that youth violence is declining—and at noteworthy rates. Between 2002 and 2014, ... young people involved in violence in the United States. The study, Trends ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... for adolescents and young adults, has kicked off its 4th annual Forum for ... This year’s theme is “Attachment Informed Therapy for Mental Health and Addiction.” ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... Allegheny County that offers services to communities throughout the greater Pittsburgh metropolitan region, ... charity drive to provide adaptive bicycles for differently-abled children. , Variety the Children’s ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... The adage ... Flex House, the next project in the company’s esteemed VISION House demonstration project series. ... use exactly the amount of resources they need to live affordably and abundantly without ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market by Manufacturers, ... and analysed the potential of Global Effective Microorganisms (EM) Market ... growth factors. The report identifies and analyses the emerging trends ... market. ... and Figures, 6 Major Company Profiles, spread across 124 pages ...
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
Breaking Medicine Technology: